Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10710890 | 0.86 | ACHE (0.42) | ACHEMMP2EPHX1ALOX15HDAC3 | |
| SCHEMBL283077 | 0.86 | MMP2 (0.38) | ACHEMMP2EPHX1HDAC3HDAC1 | |
| SCHEMBL10710670 | 0.84 | ALDH1A1 (0.41) | ACHEMMP2EPHX1ALOX15HDAC3 | |
| SCHEMBL10709009 | 0.83 | CA12 (0.42) | ACHEMMP2EPHX1ALOX15HDAC3 | |
| SCHEMBL10711304 | 0.79 | CNR2 (0.47) | — | |
| SCHEMBL10710232 | 0.79 | HDAC3 (0.39) | ACHEMMP2EPHX1ALOX15HDAC3 | |
| SCHEMBL11433505 | 0.78 | ACE2 (0.46) | EPHX1 | |
| SCHEMBL10708611 | 0.77 | HDAC3 (0.50) | ACHEHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL27620783 | 0.76 | ACHE (0.45) | ACHEMMP2EPHX1ALOX15 | |
| SCHEMBL55208 | 0.75 | MGAM (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746420-A | 1- (4- (aminomethyl) benzyl) -2-butyl-2H-pyrazolo [3,4-c ] quinolin-4-amine derivatives as Toll-like receptor (TLR)7/8 agonists and related compounds and antibody drug conjugates thereof for cancer therapy and diagnosis | 苏特罗生物制药公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3983410-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | Sutro Biopharma, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020257235-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | SUTRO BIOPHARMA, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-1646095-B2 | Stabilised silver nanoparticles and their use | XEROX CORP (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-1646095-B1 | Stabilised silver nanoparticles and their use | XEROX CORP (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| US-9145410-B2 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| EP-2411371-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-0843551-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997015570-A1 | NOVEL ACID PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR, USE THEREOF AS DRUGS, NOVEL USE THEREFOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH DERIVATIVES | HOECHST MARION ROUSSEL (FR) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997004773-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995002596-A1 | AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0106938-B1 | REACTION OF T-ALKYLHYDRAZINIUM SALTS AND ORGANIC PEROXIDES TO FOAM UNSATURATED POLYESTER RESINS | PENNWALT CORPORATION (US) | 1988-08-17 | — | — | EP | disclosed |
| EP-0002066-B1 | 2-ADAMANTYL HYDRAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Teva Pharmaceutical Industries Limited (IL) | 1983-05-25 | — | — | EP | disclosed |
| US-4254128-A | 2-Adamantyl hydrazines and biocidal compositions thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1981-03-03 | — | — | US | disclosed |
| EP-0002066-A1 | 2-Adamantyl hydrazines and pharmaceutical compositions containing them | Teva Pharmaceutical Industries Limited (IL) | 1979-05-30 | — | — | EP | disclosed |